TY - JOUR T1 - Cystic fibrosis in Europe: patients live longer but are we ready? JF - European Respiratory Journal JO - Eur Respir J SP - 11 LP - 12 DO - 10.1183/09031936.00026615 VL - 46 IS - 1 AU - Carsten Schwarz AU - Dominik Hartl Y1 - 2015/07/01 UR - http://erj.ersjournals.com/content/46/1/11.abstract N2 - Having passed the 25th anniversary of discovering the cystic fibrosis transmembrane conductance regulator (CFTR) gene, let's take a look forward to the next 25 years. Newborn screening, animal models, biomarkers, innovative drugs (prototypical CFTR modulators), and advances in lung transplantation have moved the field forward, probably faster than for any other lung disease in recent years [1–5]. As a consequence, the mean survival of patients with cystic fibrosis (CF) is steadily increasing and now exceeds 40 years of age in most European countries [6, 7] and beyond [8].This study highlights the future challenge to deal with an ageing CF population and innovative, but expensive drugs http://ow.ly/JRCnx ER -